Merck KGaA CFO Believes in Value Based Pricing

The transcript discusses Merck's recent FDA approvals for its immuno-oncology drugs and the financial implications, including flat profit projections due to increased R&D expenses. It covers Merck's pricing strategy, emphasizing value-based pricing and the balance between affordability and innovation incentives. The conversation shifts to Merck's business structure, focusing on ERP strategies and the integration of subsidiaries. The discussion also highlights Merck's debt reduction efforts and acquisition strategy, with a focus on smaller acquisitions to strengthen its pharma pipeline. Finally, the impact of R&D expenses on Merck's profit forecast is addressed.

What is the significance of the cooperation between Merck and Pfizer?

What is the current priority for Merck regarding acquisitions?

What impact do R&D expenses have on Merck's profit forecast?